Table 5.
Cox regression analyses for cardiovascular mortality and rehospitalization
| Cardiovascular mortality | Rehospitalization | |||
|---|---|---|---|---|
| Variables | HR (95% CI) | P value | HR (95% CI) | P value |
| Age | 1.04 (1.02–1.07) | <0.001 | 1.03 (1.01–1.05) | 0.002 |
| Male | 1.43 (1.05–1.94) | 0.024 | 1.38 (1.08–1.76) | 0.011 |
| BMI | 0.96 (0.92–1.01) | 0.074 | 1.00 (0.96–1.04) | 0.868 |
| Ischaemic aetiology | 2.86 (1.99–4.09) | <0.001 | 0.95 (0.74–1.21) | 0.634 |
| Hypertension | 0.98 (0.73–1.30) | 0.872 | 1.04 (0.83–1.31) | 0.731 |
| Smoking | 1.19 (0.90–1.58) | 0.227 | 0.99 (0.78–1.25) | 0.920 |
| NYHA class | 1.47 (1.15–1.89) | 0.003 | 0.97 (0.79–1.18) | 0.454 |
| LVEF | 0.98 (0.95–1.01) | 0.109 | 1.07 (1.05–1.09) | <0.001 |
| Log NT‐proBNP | 3.17 (1.21–8.31) | 0.019 | 2.63 (1.21–5.74) | 0.015 |
| eGFR | 1.01 (0.99–1.02) | 0.324 | 1.01 (1.00–1.02) | 0.046 |
| Log RBP4 | 2.24 (1.35–5.39) | 0.021 | 2.54 (1.09–5.60) | 0.035 |
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LVEF, left ventricular eject fraction; MACE, major adverse cardiac event(s); NT‐proBNP, N terminal pro brain natriuretic peptide; NYHA, New York Heart Association; RBP4, retinol‐binding protein 4.